arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Abpro Holdings, Inc.

ABPO
— Price unavailable
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
6 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
61
Health
Fair
Bullish
auto_awesome

Analytical Summary

Abpro Holdings, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC 75.6% ↗
FCF / Share $-2.69 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

6-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$183.00K
↑ +50.0% —
Net Income Profit after all expenses
$-2.89M
↑ +60.0% —
FCF / Share Free cash flow per share
$-2.69
↓ -597.4% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
94
Financial Health ↑
7
Cash Quality
87

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 6 years · 22 quarters